Patents by Inventor Ihab Younis

Ihab Younis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220073917
    Abstract: The invention provides a method of regulating U1 activity associated with its splicing role as well as its role in protecting pre-mRNAs from premature termination by cleavage and polyadenylation, thereby modulating expression of a gene or genes. In one embodiment, the invention includes compositions and methods for regulating gene expression and treating diseases associated with dysregulated gene expression.
    Type: Application
    Filed: September 22, 2021
    Publication date: March 10, 2022
    Inventors: Gideon Dreyfuss, Lili Wan, Jung Min Oh, Anna Maria Pinto, Ihab Younis, Michael George Berg, Daisuke Kaida
  • Patent number: 11142762
    Abstract: The invention provides a method of regulating U1 activity associated with its splicing role as well as its role in protecting pre-mRNAs from premature termination by cleavage and polyadenylation, thereby modulating expression of a gene or genes. In one embodiment, the invention includes compositions and methods for regulating gene expression and treating diseases associated with dysregulated gene expression.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: October 12, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Lili Wan, Jung Min Oh, Anna Maria Pinto, Ihab Younis, Michael George Berg, Daisuke Kaida
  • Patent number: 9650684
    Abstract: The present invention is based on the discovery of a cell-based system to identify novel modulators of splicing or splicing dependent processes. The cell-based system of the present invention utilizes a fast and highly sensitive reporter, that responds to defects in the splicing machinery itself and is sensitive to changes in the signals that regulate splicing dependent processes such as those that modulate the EJC, splicing-dependent export, localization or translation efficiency. The present invention further uses the cell-based screen to identify several small molecules that modulate both constitutive and alternative splicing. Accordingly, the present invention includes general or alternative splicing inhibitors identified using the assay described herein. The present invention also provides methods of treating a subject having a condition associated with aberrant target RNA expression.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: May 16, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Ihab Younis, Lili Wan
  • Publication number: 20150191724
    Abstract: The present invention relates to the discovery of a novel global gene expression regulation mechanism whereby U1 snRNP (U1) protects pre-mRNAs. In one embodiment, the invention includes compositions and methods for regulating gene expression and treating diseases associated with dysregulated gene expression.
    Type: Application
    Filed: July 5, 2013
    Publication date: July 9, 2015
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Lili Wan, Jung Min Oh, Anna Maria Pinto, Ihab Younis, Michael George Berg, Daisuke Kaida
  • Publication number: 20120157474
    Abstract: The present invention is based on the discovery of a cell-based system to identify novel modulators of splicing or splicing dependent processes. The cell-based system of the present invention utilizes a fast and highly sensitive reporter, that responds to defects in the splicing machinery itself and is sensitive to changes in the signals that regulate splicing dependent processes such as those that modulate the EJC, splicing-dependent export, localization or translation efficiency. The present invention further uses the cell-based screen to identify several small molecules that modulate both constitutive and alternative splicing. Accordingly, the present invention includes general or alternative splicing inhibitors identified using the assay described herein. The present invention also provides methods of treating a subject having a condition associated with aberrant target RNA expression.
    Type: Application
    Filed: May 21, 2010
    Publication date: June 21, 2012
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Gideon Dreyfuss, Ihab Younis, Lili Wan